Physician profile
Jonathan A Peng
NPI 1922252725
$2,989.24
in general payments reported to CMS, 2019-2025
18 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $468 · 2024: $1,178 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.35 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $469.47 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $351.10 | 2025 | Cardiomems, Amplatzer Amulet |
| Heartflow, INC. | $346.76 | 2023-2025 | Ffrct |
| Abiomed | $310.51 | 2024 | Impella |
| Medtronic, INC. | $267.26 | 2024-2025 | Symplicity G3, Micra |
| Edwards Lifesciences Corporation | $187.17 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $157.46 | 2023 | Watchman Flx, Watchman Access System |
| Philips North America LLC | $101.97 | 2024-2025 | Mcot, (5044) Mcot, (Bq9) Coronary Ivus |
| Irhythm Technologies, INC. | $53.98 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $50.13 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.97 | 2023-2025 | Lifevest |
| Stryker Corporation | $42.09 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $31.69 | 2025 | Repatha |
| Lilly USA, LLC | $28.55 | 2025 | Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $21.96 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $18.22 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.60 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.